because ultimately 2591 still has a lot of work to do. We only have human data in a very small number of patients. The phase 3 designs need to be approved, the phase 3s need to be conducted, they need to hit the endpoints, the drug needs to be approved. I do believe it will get approved, but there is still so so much to do. Nothing is guaranteed in terms of the trials being positive. I do not see any big institutional investor buying NEU right now for 2591 because of the time value of money. All this will also take multiple years from here. Best case maybe 3 years?
For the foreseeable future, the share price will be determined by trofinitede sales. Which opens the share price up to volatility.
because ultimately 2591 still has a lot of work to do. We only...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.78 |
Change
-1.360(6.14%) |
Mkt cap ! $2.656B | |||
| Open | High | Low | Value | Volume |
| $22.06 | $22.11 | $20.63 | $8.616M | 407.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 593 | $20.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.78 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |